Doxazosin Tablet
Product Images NDC 68788-8412

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 68788-8412). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Timelinedescription Automatically Generated (2110eec5 949d 4718 Ad6d 3629e5db8a07 00)

Label for Doxazosin Tablets 4 mg, a prescription oral tablet. The label displays the drug name prominently with instructions for dosage in English and Spanish, space for filling quantity and directions, and storage warnings. The label identifies the manufacturer as Apotex Corp. and the labeler as Preferred Pharmaceuticals Inc. It includes a barcode and a QR code, along with federal caution about drug transfer restrictions.*

FDA Label Image

Doxazosin-structure.jpg (Doxazosin Structure)

Chemical structure of Doxazosin, the active ingredient in the medication. The diagram illustrates the molecular arrangement, including rings, atoms, and bonds characteristic of the compound.*

FDA Label Image

Figure1.jpg (Figure1)

This image features two line graphs comparing Doxazosin 4 mg oral tablet to placebo over a 14-week treatment period. The first graph shows the mean change in total symptom score from baseline, with Doxazosin demonstrating a greater decrease than placebo. The second graph displays the mean increase in maximum urinary flow rate (mL/sec) from baseline, with Doxazosin showing a significantly higher increase relative to placebo. Both graphs include sample sizes and statistical significance markers.*

FDA Label Image

Table3.jpg (Table3)

A chart and bar graph summarizing effectiveness data from placebo-controlled trials of Doxazosin. It compares symptom scores and maximum flow rate changes between placebo, 4 mg, and 8 mg doses. The table presents mean baseline values and mean changes, while the bar graph highlights the corresponding improvements for maximum flow rate and symptom scores across study groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.